Giovanni Caforio, Bristol Myers Squibb CEO (Pablo Martinez Monsivais/AP Images)
Renegotiate the $6B CVR deal Bristol Myers made for the Celgene buyout? Caforio says that’s not happening
Bristol Myers Squibb has $6 billion riding on its CVR ($BMYRT) for the Celgene buyout, and one essential element of that is now hanging …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
